Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Durable responses seen from lisocabtagene in relapsed/refractory DLBCL
Abramson JS et al. ASCO 2018. Abstract 7505
Key clinical point: Liso-cel produced durable responses in poor-prognosis patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Major finding: Among DLBCL patients treated with the pivotal dose of liso-cel, 88% who were in complete remission at 3 months remained in complete remission at the 6 month follow-up.
Study details: Follow-up report on a cohort of DLBCL patients from TRANSCEND NHL 001, a phase 1 trial of liso-cel in relapsed and refractory B-cell NHL.
Disclosures: Dr. Abramson reported disclosures related to Celgene, Genentech/Roche, Gilead Sciences, Novartis, Seattle Genetics, and Millennium.
Citation:
Abramson JS et al. ASCO 2018. Abstract 7505.